Board of Directors

Leadership

Yuling Li

Ph.D.

Co-Founder and Chief Executive Officer

Kenneth Carter

Ph.D.

Global Head of Corporate Development & President of US Operations

Zhenhua Wu

M.Sc.

Co-Founder and Executive Vice President

Bing Zhu

MBA

Chief Financial Officer

Yingfei Wei

Ph.D.

Chief Scientific Officer

Michael Huang

Ph.D.

VP, Quality and CMC Management

Robert Valdes

MBA / M.Sc.

Senior Advisor, Engineering

Evan Goldberg

MBA

VP, Strategy and Business Development

Min Zhu

Ph.D.

VP, Technology and Manufacturing

Keke Feng

J.D.

Legal Director

Guo-Liang Yu, Ph.D.

Co-Founder and Chairman

Dr. Guo-Liang Yu is a leader in the Chinese and global biopharmaceutical communities as well as an accomplished scientist and serial entrepreneur. His many leadership roles include currently serving as the Chairman and CEO of Apollomics, an innovative US and China-based biopharmaceutical company committed to the discovery and development of oncology combination therapies. In recent years he has also been Executive Chairman of Crown Bioscience Inc. which he successfully sold to JSR Corporation, and served as a Venture Partner at OrbiMed, a premier global venture capital firm. Dr. Yu has also personally helped start several companies where he has served in a board and/or advisory role. Earlier in his career, Dr. Yu co-founded Epitomics Inc., an antibody-based biotechnology company where he served as CEO for 10 years prior the company being acquired by Abcam. Dr. Yu is the founding president of the Chinese Biopharmaceutical Association and serves on the boards of BayHelix, CABS, National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of the Pacific. Dr. Yu’s success is driven by his scientific curiosity and a passion for translating scientific discovery into real products. His challenge is balancing his time between science and business, fun and work, family and community.

×

Yuling Li, Ph.D.

Co-Founder and Board Member

Dr. Yuling Li is a seasoned and well-respected biopharmaceutical professional who has led successful product development from clinical stage through commercialization. Prior to joining Innoforce, Dr. Li was a R&D Director and Fellow at MedImmune/AstraZeneca. She started her career at Roche and later worked at Human Genome Sciences (now GlaxoSmithKline) where she held several leadership roles including Director of Purification Sciences. While serving in these positions, Dr. Li played a key role in the development of 3 approved products and contributed to over 30 clinical development programs. Additionally, she has authored over 40 publications and is the primary inventor for five issued patents.  She is a well-recognized and frequently invited speaker and advisor, and was recognized for her professional accomplishments with the prestigious Rising Star Award from the Healthcare Businesswomen’s Association. Dr. Li is also active in several industry organizations, having served as the President of the Chinese Biopharmaceutical Association and co-founding the Alliance of ALL-CABPA. She is also passionate about mentoring mid-stage biotech professionals, developing the next generation of women in leadership, and supporting the growth of young scientists. In her spare time, Dr. Li enjoys reading, sightseeing, meditation, and yoga.

×

Marietta Wu, Ph.D.

Board Member

Dr. Marietta Wu has deep expertise in cross-border ventures and value creation in the life sciences industry. She was Managing Director of Quan Capital, a founding member and COO of Zai Lab, Managing Director at Burrill & Company, acting COO of Waterstone and Director of Strategy at Edwards Lifescience. She has also held various financial and business development positions at Eli Lilly & Company. She is a founding member of the China Healthcare Investment Conference.
Dr. Wu received her Ph.D. in Medical Sciences from Medical College of Ohio, and an MBA from the University of Michigan Ross School of Business.

×

KWING-MING TSOI, EMBA

Board Member

Senior economist, graduated from school of management of Xiamen University with a master's degree (EMBA).
KWING-MING TSOI has obtained professional investment and management experience of more than 20 years in capital markets of Hong Kong and Mainland China. He is also the founder and chairman of the board of South China Venture Capital (“SCVC”), a professional asset management institution established in 2008 and with a focus on venture capital in the fields of biomedicine, semiconductor, artificial intelligence and other scientific and technological fields.

×

Zeng Liu, M.A.E

Board Member

Zeng Liu is executive director and general manager of Beijing Anhua Yanyuan Investment Co., Ltd., executive director and general manager of Ningbo Yanyuan Venture Capital Co., Ltd., executive director and general manager of Ningbo yanchuang Asset Management Group Co., Ltd., general manager of Hangzhou Yanyuan Fangrong Investment Management Co., Ltd., executive director and general manager of Ningbo Yanyuan Century Equity Investment Co., Ltd., executive director and general manager of Yaoshang Equity Investment Management Co., Ltd. of Ningbo Yanyuan, executive director and general manager of Ningbo Yanyuan Hongde investment management company, Board of Director of Zhenhai Petrochemical Engineering Co., Ltd., Board of Director of Ningbo Jujia New Materials Technology Co., Ltd. and Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
She served as secretary of the Communist Youth League Committee of the school of government management of the Communist Youth League Committee of Peking University, assistant director of the Party committee office and President's office of Peking University, assistant dean of the school of technology of Peking University, deputy secretary and member of the Party group of the Communist Youth League Committee of Lishui City, Zhejiang Province, executive director and Prime Minister of Beijing Anhua Yanyuan Investment Co., Ltd. (Preparatory).
Zeng Liu holds a bachelor's degree in management and a master's degree in economics from Peking University.

×

Yuling Li, Ph.D.

Co-Founder and Chief Executive Officer

Dr. Yuling Li is a seasoned and well-respected biopharmaceutical professional who has led successful product development from clinical stage through commercialization. Prior to joining Innoforce, Dr. Li was a R&D Director and Fellow at MedImmune/AstraZeneca. She started her career at Roche and later worked at Human Genome Sciences (now GlaxoSmithKline) where she held several leadership roles including Director of Purification Sciences. While serving in these positions, Dr. Li played a key role in the development of 3 approved products and contributed to over 30 clinical development programs. Additionally, she has authored over 40 publications and is the primary inventor for five issued patents.  She is a well-recognized and frequently invited speaker and advisor, and was recognized for her professional accomplishments with the prestigious Rising Star Award from the Healthcare Businesswomen’s Association. Dr. Li is also active in several industry organizations, having served as the President of the Chinese Biopharmaceutical Association and co-founding the Alliance of ALL-CABPA. She is also passionate about mentoring mid-stage biotech professionals, developing the next generation of women in leadership, and supporting the growth of young scientists. In her spare time, Dr. Li enjoys reading, sightseeing, meditation, and yoga.

×

Kenneth Carter, Ph.D.

Global Head of Corporate Development & President of US Operations

Dr. Kenneth Carter is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. He has been involved in starting and guiding several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors including NexImmune (NASDAQ: NEXI) which he co-founded and served for many years as Chairman and CEO, and Seneca Biopharma (NASDAQ: SNCA) where he served as Executive Chairman. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals (NASDAQ: AVRX, now part of AbbVie). Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology, and completed an IPO and multiple partnerships with top 10 pharmaceutical companies. Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. Dr. Carter is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course titled “Creating a Biotechnology Enterprise”.

×

Zhenhua Wu, M.Sc.

Co-Founder and Executive Vice President

Zhenhua Wu received his master’s degree in Project Management in University of Queensland Australia in 2009, and joined a public real estate company in Hangzhou. During his time in the real estate industry, he managed several key projects. In 2017, Zhenhua was part of the co-founding team at Innoforce. He is responsible for Innoforce public relations and construction management affairs.

×

Bing Zhu, MBA

Chief Financial Officer

Mr. Bing Zhu has more than 30 years of experience in finance, and has served as an executive in several public and private companies including multi-national companies, Fortune 500 companies, prominent Chinese entrepreneurial companies, and financial corporations. Among other roles, he served as the CFO of Gmax BioPharm LLC, CFO and COO of Crown Bioscience International where he led the IPO on TPEx in 2016, CFO of Shanghai Chemspec International where led the IPO on NYSE in 2009, and CFO of Canadian Solar Inc. where he led the IPO on NASDAQ in 2006. This broad experience base has led to Mr. Zhu having expertise in both public and private financing, IPO execution, M&A, leading strategy, commercial operations, and general management. Earlier in his career, he worked for several years in commercial banking in Toronto, Canada and was the Shanghai chief representative of Raytheon Corporation.

×

Yingfei Wei, Ph.D.

Chief Scientific Officer

Dr. Yingfei Wei is a world-class scientist and an experienced executive in the biotechnology and pharmaceutical industry, with experience in both large and small companies at various stages of development. Among other notable accomplishments during her career, Dr. Wei served as the Chief Scientific Officer for 3SBio, Inc., where she helped lead the IPO for 3SBio which was the first NASDAQ-listed Chinese biopharmaceutical company. Prior to 3SBio, Dr. Wei served as Director of Cell and Analytical Biology of the Bayer Biotech Research Division. Earlier in her career, Dr. Wei was a principal scientist at Human Genome Sciences where she played a key role in discovery of the HPNCC gene for colorectal cancer, which was named as the Science “Molecule of the Year" in 1994. She completed her postdoctoral training at Harvard School of Public Health, where her research focused on DNA damage repair. Dr. Wei is actively involved in biopharmaceutical-related associations including CABS, CBA, and BayHelix. She is also an advocate and participant in developing programs for rural early-childhood education in rural China.

×

Michael Huang, Ph.D.

VP, Quality and CMC Management

Dr. Michael Huang has extensive technical and leadership experience in Quality Operations, Biopharmaceutical Development, and CMC Management. Over the course of his career, Dr. Huang has served at several biopharmaceutical companies including Sanofi Pasteur, Merck, and AstraZeneca, as well as US Pharmacopeia, a global standard-setting organization. He has played key roles in the development and licensure of new vaccines (Menactra, Gardasil) and new mAb-based biotherapeutics (Imfinzi, Fasenra, Lumoxiti, Adtralza) as well as in commercial operations and market supply for vaccines and biotherapeutic products. Dr. Huang has more than two decades of experience leading quality and CMC projects in the US, as well as extensive experience in China and Europe, including due diligence, joint venture management, regulatory submissions, program audits, and drug substance and fill-finish manufacturing management. In addition to his leadership in the biopharmaceutical community, Dr. Huang is a strong advocate for US-China culture exchange, which includes volunteering as a teacher for families with adopted children, business travelers, other community members, and cross-cultural awareness training in both China and the US.

×

Robert Valdes, MBA / M.Sc.

Senior Advisor, Engineering

Mr. Robert Valdes is an accomplished entrepreneur and engineer with over 25 years of experience in the GMP manufacturing sector. Bringing an innovative and commercial-thinking perspective to projects in biotechnology manufacturing, Mr. Valdes founded and currently serves as GMP Consultant for Biotech Resources Group in Maryland, USA, and InnoAsia Co. Ltd., a joint venture established in Hangzhou, China as a horizontal extension of Biotech Research Group. Previously, Mr. Valdes served as Director of Large-Scale Manufacturing at Human Genome Sciences, where he oversaw the clinical and commercial manufacturing for the company’s first commercial product. He was the first manufacturing engineer hired by HGS in 2000 for their Large-Scale Manufacturing facility design effort, during which he played a key role from business concept to commercialization. Mr. Valdes also served as Supervisor of Commercial Manufacturing/Upstream at Lonza Biologics (US/UK) with leadership roles in GMP manufacturing design and operations. In addition to being a respected leader in global biopharmaceutical manufacturing, Mr. Valdes is passionate about traveling, cycling, and global business start-ups.

×

Evan Goldberg, MBA

VP, Strategy and Business Development

Mr. Evan Goldberg is a seasoned pharmaceutical & biotechnology professional with over 20 years of experience in marketing, strategy, business development, investment banking, and private equity. In both the US and globally, he led the completion of a range of business development transactions including acquisitions/divestitures, joint ventures, in-licensing & out-licensing partnerships, and financings. He has over a decade of international experience in China, Asia-Pacific, and Europe, including commercial responsibility for portfolios with revenue of $1-2B USD in a variety of disease areas. Prior to joining Innoforce, Mr. Goldberg was Senior Director of Strategy for Pfizer’s Upjohn Division where he focused on business growth & value creation. Mr. Goldberg also served as Head of Strategy & Business Development for Pfizer’s China business, and regional marketing team lead for Pfizer in Asia-Pacific & Europe. Earlier in his career, he worked in a variety of business positions at Wyeth, RoundTable Healthcare Partners, and Bear Stearns’ Investment Banking group. Mr. Goldberg received his MBA from Kellogg School of Management and undergraduate degree in Finance at Emory University.

×

Min Zhu, Ph.D.

VP, Technology and Manufacturing

Dr. Min Zhu is a well-respected professional in the biopharmaceutical industry, with over 17 years of experience in process development, characterization, and validation support. Prior to joining Innoforce, Dr. Zhu served as Director of Protein Science at Boehringer Ingelheim in Fremont. At BI, she was responsible for CMC strategy and cross-functional alignment from process characterization to BLA submission. In addition, she led the technology development and implementation of a next-generation continuous manufacturing platform. Before that, Dr. Zhu led downstream commercial process development, process characterization and validation for several late-stage biologic pipeline products at MedImmune/AstraZeneca. Dr. Zhu has published more than twenty papers in peer-reviewed journals and is a frequent speaker in international biopharmaceutical conferences. In addition to her leadership in the biopharmaceutical community, Dr. Zhu is also passionate about photography and traveling.

×

Keke Feng, J.D.

Legal Director

Ms. Keke Feng brings over 15 years of corporate legal experience to Innoforce Pharmaceuticals, having served both US and China-based companies. Prior to Innoforce, Keke held in-house counsel positions with Eli Lilly (China) and ChinaBio Group, and worked with US-based law firms Motley Rice, Wilson Sonsini, and Perkins Coie. She has also served as an independent counsel to several US-based biotech companies, assisting with their China operations and cross-border transactions. Previously, Keke clerked for Judge Jeffrey Barton, Superior Court of California, and assisted the State of California Department of Justice Attorney General’s Office on corporate litigation matters. She has also been a visiting scholar to Duke University for subjects in law and international relations. Keke holds a J.D., summa cum laude, from Thomas Jefferson School of Law, where she also served as Editor for the Thomas Jefferson Law Review. She is licensed to practice in the State of California as well as the U.S. Federal Court.

×
Top